Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 245

Sort by

Sort Order Select

Journal Articles

Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study

Alfonso J Tafur, MD MS, Na Li, PhD, Nathan Clark, PharmD, Sam Schulman, MD PhD FRCPC, Alex Spyropoulos, MD, Joseph A Caprini, MD MS, FACS, RVT, James Douketis, MD

Blood (2019) 134 (Supplement_1): 710.

https://doi.org/10.1182/blood-2019-125292

Published: 2019

Journal Articles

High Rates of Venous and Arterial Thrombotic Events in POEMS Patients: Results from the UK-Based POEMS Registry, Highlighting the Need for Therapeutic Guidelines

Zara Sayar, MD FRCPath, MRCP, Anna Weatherill, Stephen Keddie, Jonathan Sive, MD, Michael P Lunn, Mari Thomas, Shirley D'Sa

Blood (2019) 134 (Supplement_1): 714.

https://doi.org/10.1182/blood-2019-125639

Published: 2019

Journal Articles

Effects of Andexanet Alfa on Thrombin Generation in Bleeding Associated with Factor Xa Inhibitors

Michiel Coppens, MD, Lizhen Xu, PhD, Roisin Bavalia, MD, Saskia Middeldorp, MD PhD, Peter Verhamme, MD PhD, John W. Eikelboom, MBBS, MSc, FRACP, FRCPA, Mark Crowther, MD, Genmin Lu, Patrick Yue, MD, Pamela B. Conley, PhD, Stuart J. Connolly, MD MSc, FRCPC

Blood (2019) 134 (Supplement_1): 711.

https://doi.org/10.1182/blood-2019-124596

Published: 2019

Journal Articles

Prothrombin Complex Concentrates (PCCs) Have Limited Effect on TF-Initiated Thrombin Generation in FXa Inhibitor-Anticoagulated Plasma: In Vitro Comparison between Direct Reversal By Andexanet Alfa and "Work Around" By PCCs

Genmin Lu, Joyce P. Lin, BS, Khanh Bui, BS, John T. Curnutte, MD PhD, Pamela B. Conley, PhD

Blood (2019) 134 (Supplement_1): 713.

https://doi.org/10.1182/blood-2019-124864

Published: 2019

Journal Articles

Andexanet Alpha Differentially Neutralizes the Anticoagulant, Antiprotease and Thrombin Generation Inhibitory Effects of Unfractionated Heparin, Enoxaparin and Fondaparinux

Fakiha Siddiqui, Alfonso J Tafur, MD MS, Debra Hoppensteadt, PhD, Jeanine Walenga, PhD, Walter Jeske, PhD, Emily Bontekoe, Ahmed Kouta, Jawed Fareed, PhD

Blood (2019) 134 (Supplement_1): 1158.

https://doi.org/10.1182/blood-2019-127072

Published: 2019

Journal Articles

Safety and Efficacy of Apixaban Versus Enoxaparin/Warfarin in Patients with Extremes of Body Weight: Post-Hoc Analysis of the AMPLIFY Trial

Theodore Lee, MD, Sharon Pan, Wonkyung Byon, Bushra S Ilyas

Blood (2019) 134 (Supplement_1): 1152.

https://doi.org/10.1182/blood-2019-121542

Published: 2019

Journal Articles

Modified Anti-FXa Assays for Measuring the Residual Activity of Apixaban and Rivaroxaban in Andexanet Alfa-Containing Samples on the ACL TOP Family ® Coagulation Analyzers

Anuja Khan, PhD, Krisjela Shishko, BS, Sam Arcidiacono, BS, Khanh Bui, BS, Genmin Lu, Pamela B. Conley, PhD, Anne Winkler, MD

Blood (2019) 134 (Supplement_1): 1153.

https://doi.org/10.1182/blood-2019-126254

Published: 2019

Journal Articles

The Use of Direct Oral Anticoagulants in Non-Cirrhotic Portal Vein Thrombosis

Leonard Naymagon, MD, Douglas Tremblay, MD, Nicole Zubizarreta, MPH, Erin Moshier, MS, Thomas Schiano, MD, John Mascarenhas, MD

Blood (2019) 134 (Supplement_1): 1154.

https://doi.org/10.1182/blood-2019-124042

Published: 2019

Journal Articles

Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban By Andexanet Alfa As Measured By Whole Blood Thromboelastographic Analysis

Siddharth Mehrotra, Debra Hoppensteadt, PhD, Walter Jeske, PhD, Omer Iqbal, MD, Alfonso J Tafur, MD MS, Bruce Lewis, Jawed Fareed, PhD

Blood (2019) 134 (Supplement_1): 1155.

https://doi.org/10.1182/blood-2019-131907

Published: 2019

Journal Articles

Characterizing the Use of Direct Oral Anticoagulants in Children Using the American Thrombosis and Hemostasis Network Dataset (ATHNdataset)

Jennifer G. Davila, MD, Dunlei Cheng, PhD, Leslie J. Raffini, MD, Courtney D. Thornburg, MD, Fernando F. Corrales-Medina, MD

Blood (2019) 134 (Supplement_1): 1156.

https://doi.org/10.1182/blood-2019-128324

Published: 2019

Journal Articles

Impact of Adding Aspirin to Direct Oral Anticoagulant Therapy without an Apparent Indication

Jordan K Schaefer, MD, Yun Li, PhD, Xiaowen Kong, MA, Tina Alexandris-Souphis, RN, Mona A Ali, PharmD, Brian Haymart, RN, MS, Scott Kaatz, DO, MSc, Eva Kline-Rogers, RN, MS, Jay H Kozlowski, MD, Gregory D Krol, Sahana R Shankar, Suman L Sood, MD, James B Froehlich, MD MPH, Geoffrey D Barnes, MD MSc

Blood (2019) 134 (Supplement_1): 787.

https://doi.org/10.1182/blood-2019-122526

Published: 2019

Journal Articles

Differences in Admission Rates Among Patients Treated with Apixaban Vs. Warfarin for Venous Thromboembolism in the Emergency Department

Steven Deitelzweig, MD, Patrick Hlavacek, MPH, Jack Mardekian, PhD, Lisa Rosenblatt, MD MPH, Cristina Russ, MD PhD, Kenneth Tuell, RPh, Melissa Lingohr-Smith, PhD, Jay Lin, PhD MBA, Jennifer D Guo, PhD

Blood (2019) 134 (Supplement_1): 2157.

https://doi.org/10.1182/blood-2019-125845

Published: 2019

Journal Articles

Treatment of Upper Extremity Deep Vein Thrombosis with Apixaban and Rivaroxaban

Damon E. Houghton, MDMS, Jordan Cochuyt, David O. Hodge, MS, Danielle Vlazny, PA-C, Ana I Casanegra, MD, Lisa Peterson, RN, David A Froehling, MD, Robert D. McBane, MD, Waldemar E. Wysokinski, MD PhD

Blood (2019) 134 (Supplement_1): 2158.

https://doi.org/10.1182/blood-2019-125099

Published: 2019

Journal Articles

Providers Increased the Use of Direct Oral Anticoagulants in Patients with Cancer-Associated Thromboembolism without Gaining Complete Confidence: A Health System-Wide Retrospective Registry Study and a Providers' Survey

Alexander B Pine, MD PhD, Alfred I Lee, MD PhD

Blood (2019) 134 (Supplement_1): 2097.

https://doi.org/10.1182/blood-2019-130200

Published: 2019

Journal Articles

Patterns of VTE Treatment with Noac in Cancer Patients - Results of the Prospective Dresden Noac Registry (NCT01588119)

Sandra Marten, MD, Luise Tittl, Christiane Naue, MD, Jan Beyer-Westendorf, MD

Blood (2019) 134 (Supplement_1): 3667.

https://doi.org/10.1182/blood-2019-126535

Published: 2019

Journal Articles

Administration of Andexanet Alfa for Direct Factor Xa Inhibitor Reversal Precludes Therapeutic Heparinization for Cardiopulmonary Bypass

Nabil K. Thalji, MD PhD, Prakash A Patel, MD, Rodney M. Camire, PhD

Blood (2019) 134 (Supplement_1): 3640.

https://doi.org/10.1182/blood-2019-125955

Published: 2019

Journal Articles

Bleeding Risk in Non-Valvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants and Warfarin: A Systematic Review and Meta-Analysis of Observational Studies

Yimin Pearl Wang, BSc, Rohan Kehar, MDMSc,FRCPC, Alla Iansavitchene, BSc, Alejandro Lazo-Langner, MD MSc

Blood (2019) 134 (Supplement_1): 3672.

https://doi.org/10.1182/blood-2019-123870

Published: 2019

Journal Articles

Provider Practices Regarding Prophylactic Anticoagulation in Children with Leukemia

Nicole Kucine, MD, Melanie Degliuomini, MD, Elizabeth Mauer, MS, Victoria Cooley, MS, Linda M Gerber, PhD, Suchitra Acharya, MD

Blood (2019) 134 (Supplement_1): 3412.

https://doi.org/10.1182/blood-2019-123084

Published: 2019

Journal Articles

Efficacy and Safety of Direct Oral Anticoagulants in Obese Patients with Venous Thromboembolism

Renata Almeida Sa, MSc, BSc, Fatimah Al-Ani, MD MRCP, Alejandro Lazo-Langner, MD MSc, Martha L Louzada, MDMSc

Blood (2019) 134 (Supplement_1): 3675.

https://doi.org/10.1182/blood-2019-121765

Published: 2019

Journal Articles

Concurrent Treatment of VEGFR Tyrosine Kinase Inhibitors (TKIs) and Factor Xa Inhibitors Is Associated with Increased Bleeding Risks

Sandip Patel, MBBS, Tiffany George, MD, Tzu-Fei Wang, MD MPH, Sherry Mori Vogt, Pharm D, Edmund Folefac, MD, Ming Yin, MD

Blood (2019) 134 (Supplement_1): 3681.

https://doi.org/10.1182/blood-2019-130465

Published: 2019

NARROW

Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study

High Rates of Venous and Arterial Thrombotic Events in POEMS Patients: Results from the UK-Based POEMS Registry, Highlighting the Need for Therapeutic Guidelines

Effects of Andexanet Alfa on Thrombin Generation in Bleeding Associated with Factor Xa Inhibitors

Prothrombin Complex Concentrates (PCCs) Have Limited Effect on TF-Initiated Thrombin Generation in FXa Inhibitor-Anticoagulated Plasma: In Vitro Comparison between Direct Reversal By Andexanet Alfa and "Work Around" By PCCs

Andexanet Alpha Differentially Neutralizes the Anticoagulant, Antiprotease and Thrombin Generation Inhibitory Effects of Unfractionated Heparin, Enoxaparin and Fondaparinux

Safety and Efficacy of Apixaban Versus Enoxaparin/Warfarin in Patients with Extremes of Body Weight: Post-Hoc Analysis of the AMPLIFY Trial

Modified Anti-FXa Assays for Measuring the Residual Activity of Apixaban and Rivaroxaban in Andexanet Alfa-Containing Samples on the ACL TOP Family ® Coagulation Analyzers

The Use of Direct Oral Anticoagulants in Non-Cirrhotic Portal Vein Thrombosis

Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban By Andexanet Alfa As Measured By Whole Blood Thromboelastographic Analysis

Characterizing the Use of Direct Oral Anticoagulants in Children Using the American Thrombosis and Hemostasis Network Dataset (ATHNdataset)

Impact of Adding Aspirin to Direct Oral Anticoagulant Therapy without an Apparent Indication

Differences in Admission Rates Among Patients Treated with Apixaban Vs. Warfarin for Venous Thromboembolism in the Emergency Department

Treatment of Upper Extremity Deep Vein Thrombosis with Apixaban and Rivaroxaban

Providers Increased the Use of Direct Oral Anticoagulants in Patients with Cancer-Associated Thromboembolism without Gaining Complete Confidence: A Health System-Wide Retrospective Registry Study and a Providers' Survey

Patterns of VTE Treatment with Noac in Cancer Patients - Results of the Prospective Dresden Noac Registry (NCT01588119)

Administration of Andexanet Alfa for Direct Factor Xa Inhibitor Reversal Precludes Therapeutic Heparinization for Cardiopulmonary Bypass

Bleeding Risk in Non-Valvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants and Warfarin: A Systematic Review and Meta-Analysis of Observational Studies

Provider Practices Regarding Prophylactic Anticoagulation in Children with Leukemia

Efficacy and Safety of Direct Oral Anticoagulants in Obese Patients with Venous Thromboembolism

Concurrent Treatment of VEGFR Tyrosine Kinase Inhibitors (TKIs) and Factor Xa Inhibitors Is Associated with Increased Bleeding Risks

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only